FULC Q1 2021 Earnings — Fulcrum Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FULCFulcrum Therapeutics, Inc.

$436M

Q1 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$5M+538.5% YoY

Gross Profit

-$12M-241.1% margin

Operating Income

-$17M-355.9% margin

Net Income

-$17M-355.0% margin

EPS (Diluted)

$-0.54

QoQ Revenue Growth

+13.3%

Cash Flow

Operating Cash Flow

-$16M

Free Cash Flow

-$16M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$156M

Total Liabilities

$29M

Stockholders' Equity

$128M

Cash & Equivalents

$101M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$5M	$750,000	+538.5%
Gross Profit	-$12M	-$14M	+15.9%
Operating Income	-$17M	-$19M	+9.3%
Net Income	-$17M	-$18M	+7.9%